-
5 days ago | 
moneyshow.com | John McCamant
Celldex Therapeutics Inc. (CLDX) delivered another unprecedented clinical update for barzolvolimab (“barzo”) in CSU, further cementing the antibody’s position as the leading compound to change clinical practice in this disease of suffering, remarks John McCamant, editor of Medical Technology Stock Letter.
The company reviewed the 76-week data of barzo demonstrating incredible durability in patients off-drug for seven months. The data was presented at the EAACI conference in Glasgow on Friday.
-
2 months ago | 
moneyshow.com | John McCamant
Skye Bioscience Inc. (SKYE) provided new preclinical data using the proprietary human CB1 knock-in diet-induced obesity (DIO) mice model, showing higher-dose nimacimab could achieve a similar degree of weight loss compared to monlunabant and tirzepatide alone, writes John McCamant, editor of Medical Technology Stock Letter.
-
Jan 30, 2025 | 
moneyshow.com | John McCamant
We are recommending Skye Bioscience Inc. (SKYE) as our next investment opportunity in treating metabolic disease/obesity. Skye is developing a peripheral restricted CB1 antibody — nimacimab — to treat obesity by restoring leptin sensitivity and increasing fat metabolism, while avoiding the CB1-induced THC/neuro side effects, says John McCamant, editor of Medical Technology Stock Letter.
-
Jan 29, 2025 | 
moneyshow.com | John McCamant
Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver inflammation/NASH, suggests John McCamant, editor of Medical Technology Stock Letter.
MDGL’s recently approved pill is called Rezdiffra and it had a very strong 3Q.
-
Nov 17, 2024 | 
moneyshow.com | John McCamant
The launch of Madrigal Pharmaceuticals Inc.’s (MDGL) NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now has a market cap of close to $8 billion. Madrigal has been a long-time top pick, highlights John McCamant, editor of Medical Technology Stock Letter.
-
Sep 25, 2024 | 
moneyshow.com | John McCamant
The long awaited and overdue half-point cut in the federal funds rate was the impetus for the SPDR Biotech ETF (XBI) to finally break above the 102-103 level after three or four attempts. Meanwhile, Bicycle Therapeutics Plc (BCYC) had a strong ESMO following promising new data for BT8009, BT5528, and BT7480, explains John McCamant, editor of The Medical Technology Stock Letter.
-
Jul 15, 2024 | 
moneyshow.com | John McCamant
The long-awaited and overdue market rotation into biotech began last week, as the mega-tech trillion-dollar valuations finally receded. With bios languishing for the majority of the year, it didn’t take much to move our group and cause a breakout of the SPDR S&P Biotech ETF (XBI), observes John McCamant, editor of The Medical Technology Stock Letter.
The index closed at 98 last week, its highest level since the beginning of March.
-
Apr 29, 2024 | 
moneyshow.com | John McCamant
Incyte Corp. (INCY) announced that it has entered into a definitive agreement to acquire Escient Pharmaceuticals (a private company) for $750 million. The company’s key drug development candidates include EP262, a first in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist, writes John McCamant, editor of The Medical Technology Stock Letter.
-
Apr 9, 2024 | 
moneyshow.com | John McCamant
In a widely anticipated clinical trial in the blockbuster GLP class, Viking Therapeutics (VKTX) released excellent Phase I data for Oral ‘2735 at 28 days in obese patients, observes John McCamant, editor of The Medical Technology Stock Letter.
The company reported both excellent efficacy of 5.3% weight loss at the highest dose in just one month along with a clean safety profile.
-
Mar 5, 2024 | 
moneyshow.com | John McCamant
Viking Therapeutics (VKTX) shares recently soared when it released excellent Phase 2 SubQ data for VK2735 (GLP-1/GIP) showing treated patients lost up to 14.7% of their body weight over 13 weeks, in a clean, dose-dependent manner with high statistical significance (p<0.0001). The primary endpoint win is a 13.1 percentage point reduction in weight compared to the placebo group, explains John McCamant, editor of The Medical Technology Stock Letter.
